Gornitzky represents Kadimastem in a drug screening collaboration agreement with Merck-Serono

April 30th, 2012 Back to all news

Gornitzky represented Kadimastem Ltd. in their successful negotiations with Merck Serono S.A. for the entry into a long-term collaboration between the companies in drug discovery and screening to discover new drugs for the treatment of the neurological disease Multiple Sclerosis. As part of the joint project between the two companies, Kadimastem's innovative and breakthrough platform, using human stem cells-derived functional tissues, will be applied to test potential new drugs for the treatment of the neurological disease.


Kadimastem is an Israeli biotechnology company focused on the industrial development and commercialization of human pluripotent stem cell-based products for the pharmaceutical and/or medical treatment of diabetes, neurodegenerative diseases and other indications.


Mr. Yoram Arad (Partner) and Mr. Idan Baki (Partner) led the representation.